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Abstract 
Many common genetic factors have been identiﬁed to contribute to Parkinson’s disease 
(PD) suscepti-bility, improving our understanding of the related underlying biological 
mechanisms. The involvement of rarer variants in these loci has been poorly studied. Using 
International Parkinson’s Disease Genomics Consortium data sets, we performed a 
comprehensive study to determine the impact of rare variants in 23 previously published 
genome-wide association studies (GWAS) loci in PD. We applied Prix ﬁxe to select the 
putative causal genes underneath the GWAS peaks, which was based on underlying 
functional similarities. The Sequence Kernel Association Test was used to analyze the joint 
effect of rare, common, or both types of variants on PD susceptibility. All genes were tested 
simultaneously as a gene set and each gene individually. We observed a moderate 
association of common variants, conﬁrming the involvement of the known PD risk loci 
within our genetic data sets. Focusing on rare variants, we identiﬁed additional association 
signals for LRRK2, STBD1, and SPATA19. Our study suggests an involvement of rare variants 
within several putatively causal genes underneath previously identiﬁed PD GWAS peaks. 
 
1. Introduction 
Genetic factors play an important role in Parkinson’s disease (PD) pathogenesis. In addition 
to the discovery of rare variants using family based linkage studies, resulting in the 
identiﬁcation of, for example, SNCA, LRRK2, parkin, DJ-1, PINK1, and VPS35, numerous 
genome-wide association studies (GWAS) have shown that com-mon genetic variants 
increase PD risk (Bras et al., 2015). The most recent and largest PD association study (Nalls 
et al., 2014) identiﬁed over 20 common risk variants, conﬁrming many previously associated 
risk factors. 
Nevertheless, heritability estimates indicate that additional genetic risk factors remain to be 
discovered since a relatively large fraction of PD heritability cannot be explained by known 
PD risk loci or Mendelian genes (Do et al., 2011; Keller et al., 2012; Pihlstrom and Toft, 
2011). GWAS approaches are primarily designed to identify common risk variants by the 
usage of geno-typing arrays. However, emerging evidence suggests that rare var-iants may 
explain part of the missing heritability (Manolio et al., 2009; Zuk et al., 2014). Rare variants 
in protein-coding regions are more likely to affect the function of a gene than common var-
iants, which tag the causal variants via linkage disequilibrium (LD) and are often located in 
noncoding regions of the genome (Nelson et al., 2012; Tennessen et al., 2012). Therefore, 
rare variants might be of more importance to complex diseases than predicted by the 
Common DiseaseeCommon Variant hypothesis (Botstein and Risch, 2003; Lander, 1996; 
Pritchard and Cox, 2002; Sharma et al., 2014). In contrast to GWAS, exome sequencing 
studies aim at systemati-cally analyzing coding regions of the genome to identify causal 
variants in complex diseases (Kiezun et al., 2012). Exome studies have been proven to be 
effective for studying familial diseases (Bamshad et al., 2011), but an increasing number of 
applications for population-based studies have been developed (Cirulli et al., 2015; Purcell 
et al., 2014). 
In PD, multiple genes have been shown to harbor both common and rare variants, which 
contribute to disease pathogenesis. SNCA and LRRK2 both contain PD riskeassociated rare 
variants with Mendelian effects as common variants that increase PD risk in sporadic 
patients (Edwards et al., 2010; Nalls et al., 2011, 2014; Paisan-Ruiz et al., 2004; 
Polymeropoulos et al., 1997; Simon-Sanchez et al., 2009; Zimprich et al., 2004). GBA, for 
which an as-sociation was ﬁrst seen in families with Gaucher’s disease and parkinsonism 
(Goker-Alpan et al., 2004), is furthermore shown to play a role in PD by both rare coding 
variants and common risk variants (Do et al., 2011; Nalls et al., 2014; Pankratz et al., 2012). 
Thus, we hypothesize that rare coding variants in the known risk loci for sporadic PD are 
involved in the genetic etiology of PD. The combined effect of rare variants within recently 
identiﬁed PD risk loci will likely explain an additional portion of PD heritability. We aim to 
assess this hypothesis by determining the genetic burden of rare variants in the PD risk loci 
using 2 exome cohorts of the In-ternational Parkinson’s Disease Genomics Consortium 
(IPDGC). 
 
2. Methods 
2.1. Subjects 
All PD cases included in this study have given written informed consent. Relevant local 
ethical committees for medical research approved involvement in genetic studies. The PD 
patients were diagnosed using the UK Brain Bank criteria (Hughes et al., 1992). 
2.2. Whole exome sequencing data set. The whole exome sequencing (WES) data set 
includes 1167 PD cases and 1685 controls (post QC) of European ancestry. The PD patients 
have a tendency toward a young age of onset with an average of 41.2 years (SD ¼ 10.9). 
1201 controls originate from the Rotterdam Study, version 1 (RSX1), as we merged the 
IPGDC WES data with the RSX1 WES data (Hofman et al., 2015). The samples were 
sequenced in different batches with 2 exome capture kits: EZ Exome Library v2.0 
(Roche/Nimblegen) and Truseq Exome Enrich-ment Kit targeting 44.1 Mb and 62 Mb, 
respectively (Supplementary Table 1). To account for putative technical differences between 
the different capture kits, we only considered variants that were tar-geted by both capture 
protocols and included preQC individual sample missingness (as a reference to sequencing 
coverage) as covariates during all genetic analyses. 
 
On average, 94.4% of the exome was covered for at least 10x. The 100-bp paired-end reads 
were sequenced on a HiSeq2000 and aligned to the human reference genome (build hg19) 
using Barrow Wheeler Aligner (Li and Durbin, 2009). Genome Analysis Toolkit (McKenna et 
al., 2010) called single nucleotide variants and small insertions/deletions (indels) for each 
sample, resulting in individual gVCF ﬁles. Genotypes of all IPDGC and RSX1 exome samples 
were then jointly called and recalibrated, allowing to merge the distinct WES data sets in a 
correct manner. Standard Genome Analysis Toolkit ﬁlter steps were applied, together with a 
minimum geno-type quality Phred score of 20 and depth of 8, to only select high-quality 
variants. Only biallelic calls were considered that were located in regions targeted by both 
capture kits. Supplementary Table 2 reports the exons that have been excluded due to 
insufﬁ-cient coverage within one of the exome capture protocols. 
2.3. NeuroX data set 
The NeuroX data set encompasses 6801 PD cases and 5970 controls (post QC) of European 
ancestry. Overlapping samples with the WES data set were excluded. The average age of 
onset of the PD patients is 63.0 years (SD ¼ 12.4). The Exome NeuroX array (Nalls et al., 
2015) was used consisting of w240,000 exonic variants standard to the Illumina 
HumanExome array v1.1 and w25,000 variants focused on neurologic and 
neurodegenerative diseases. 
2.4. Quality procedures 
For individual QC in both the WES and the NeuroX data sets, samples were removed when 
showing gender ambiguity, dubious heterozygosity/genotype calls, evidence of relatedness, 
or being a population outlier. The latter 2 were calculated with LD-pruned common variants. 
Variant QC procedures were slightly different for the 2 different data sets. For the WES data 
set, variants passed QC when having a minimum call rate >85% and being in Har-
dyeWeinberg equilibrium (HWE p-values >1e-8 based on con-trols). For the NeuroX data set, 
variants were excluded for subsequent analyses with a minimum call rate <95%, an HWE p-
value <1e-6, or with signiﬁcant differences in missingness rate between cases and controls. 
2.5. Causal gene selection within PD risk loci 
Based on the most recent and largest GWAS (Lill et al., 2012; Nalls et al., 2014), we selected 
26 loci containing at least 1 top single nucleotide polymorphism (SNP) nominated in meta-
analysis with p < 5.00e-08 (as reported by pdgene.org). The published SNPs associated with 
PD are not the causal variants but rather tag the unknown causal variants with which they 
are in LD. As the causal variant (and therefore also the related gene) has not been deter-
mined for most of the PD risk loci, we explored the involvement of rare variants in PD 
susceptibility by using the Prix ﬁxe strategy, which selects 1 gene per locus based on 
functional similarities of genes within the LD-blocks from the different loci. 
The functional similarity is deﬁned as the degree of shared biological function and is 
determined by overlapping biological features such as protein domains, transcription factor 
binding sites, gene expression, phylogenetic proﬁles, and protein-protein in-teractions. 
Based on these features, cofunction networks are generated which connect genes that are 
likely to share the same underlying molecular pathway. Genes that are strongly connected 
to other candidate genes obtain a higher Prix ﬁxe score and therefore prioritized as causal 
gene. As this approach is based on genome-wide data sets and is not performed with 
disease-related biological assumptions, the Prix ﬁxe strategy aims to prioritize 
 
Table 1 
Selected set of genes 
 
 
 
P-value, meta p-value as reported on pdegene.org; seeding SNP, input SNP for Prix ﬁxe 
software; prix ﬁxe gene, genes selected based on underlying functional simi-larities, which is 
determined by overlapping biological features such as protein domains, transcription factor 
binding sites, gene expression, phylogenietic proﬁles and protein-protein interactions. 
genes without the usual text mining bias caused by literature-based knowledge (Edwards et 
al., 2011). 
The most signiﬁcantly associated SNPs from the recent meta-analysis by Nalls et al. (2014) 
were used as seeding SNPs to deﬁne the LD region per PD locus. If an SNP was not 
applicable to be used as seeding SNP (not present in either the current dbSNP 137 or 
HapMap public resources), the next strongest associated SNP or an SNP in high LD (r2 >0.8) 
within the same locus was used as a seed. We were unable to deﬁne a legitimate seeding 
SNP for 3 loci (rs71628662, rs591323, rs2414739). LD-regions were based on the CEU phase 
III population with a minimal R2 of 0.5. The ﬁnal Prix ﬁxe gene set consists of 23 genes for 
downstream analyses (Table 1). 
 
2.6. Variant selection 
To enrich both genetic data sets for deleterious variants, we selected multiple subsets of 
variants, differing in the method and stringency to select pathogenic variants. Based on 
variant annota-tion with annotate variation (Wang et al., 2010), 3 distinct subsets of 
variants were created, including: (1) all exonic variants (disruptive, splicing, 
[non]synonymous, and [non]frameshift indels); (2) amino acidechanging variants (same as 
previous except for synonymous); and (3) amino acidechanging (AAchanging) variants that 
are pre-dicted to be deleterious. The latter subset includes variants that are predicted to be 
pathogenic (Combined Annotation Dependent Depletion [CADD] score ฀12.37 (Amendola et 
al., 2015)) by Com-bined Annotation Dependent Depletion, v1 (Kircher et al., 2014). Fig. 1 
displays a workﬂow of the classiﬁcation of the different variant subsets. The exonic subset 
was exclusively tested for the gene set analysis to determine the involvement of the known 
PD risk loci in the WES and NeuroX data set.  
On average, 94.4% of the exome was covered for at least 10x. The 100-bp paired-end reads 
were sequenced on a HiSeq2000 and aligned to the human reference genome (build hg19) 
using Barrow Wheeler Aligner (Li and Durbin, 2009). Genome Analysis Toolkit (McKenna et 
al., 2010) called single nucleotide variants and small insertions/deletions (indels) for each 
sample, resulting in individual gVCF ﬁles. Genotypes of all IPDGC and RSX1 exome samples 
were then jointly called and recalibrated, allowing to merge the distinct WES data sets in a 
correct manner. Standard Genome Analysis Toolkit ﬁlter steps were applied, together with a 
minimum geno-type quality Phred score of 20 and depth of 8, to only select high-quality 
variants. Only biallelic calls were considered that were located in regions targeted by both 
capture kits. Supplementary Table 2 reports the exons that have been excluded due to 
insufﬁ-cient coverage within one of the exome capture protocols. 
 
2.7. Variant aggregation analysis 
The Sequence Kernel Association Test (SKAT) (Ionita-Laza et al., 2013; Wu et al., 2011) was 
used to perform burden analyses. The MAF threshold, separating the rare and common 
variants, was based on the total sample size using the formula (T ¼ 1/(O(2n)) suggested by 
SKAT (Ionita-Laza et al., 2013), therefore resulting in the MAF thresholds of 0.013 and 0.006 
for the WES data set and NeuroX data set, respectively. We performed polygenetic burden 
analyses for exclusively rare variants, exclusively common variants and both types of 
variants together. The common variants were pruned (PLINK (Purcell et al., 2007) indep 
settings 50 5 1.5) aiming to only consider independent variants in our genetic analyses. For 
the gene sets, we performed a 2-sided SKAT test allowing variants within a gene-set to have 
different directions and magnitudes of effects, which is in concordance with both damaging 
and protective effect estimates observed for the 23 published PD loci. To test individual 
genes, we performed a 1-sided burden test, as we hy-pothesized that variants in individual 
genes are likely to have the same direction of effect. We also performed a 2-sided SKAT 
analysis per gene in case we were interested which genes are driven an observed rare 
variant association in the total gene set. 
To correct for confounding factors (e.g., population stratiﬁcation and technical artifacts), we 
included 20 multidimensional scaling components, gender, individual missingness rate 
preQC (as a reference to the individual WES coverage) and gender for the WES data set. As 
the NeuroX data set is more homogeneous, we corrected for the ﬁrst 4 MDS components 
and gender. Empirical p-values were calculated for sig-niﬁcant sample results (p < 0.05). For 
the gene set analysis, the original sample p-value of the gene set of interest was compared 
to p values of 1000 randomly drawn gene sets of the same size. For the individual gene 
associations, empirical p-values were calculated using the resampling method implemented 
by SKAT, by 10,000 permutations of the affection status. Empirical p-values are calculated 
by (n1þ1)/(nþ1), where n1 ¼ the number of resampling p-values smaller than the original 
sample p-value and n ¼ the number of resampling. 
 
2.8. Power calculations 
We estimated the power of our study design to detect rare variant associations. 
Supplementary Table 3 displays the parame-ters that were chosen for the calculations. For 
both data sets, the PD prevalence was set to 0.0057 (Pringsheim et al., 2014). As approx-
imately half of the loci in PDgene.org have an odds ratio below 1, the percentage protective 
effect was set to 50%. A thousand simulations (a ¼ 0.025) were performed on a haplotype 
matrix of SKAT, mimicking linkage disequilibrium structure of European ancestry, comprising 
10,000 haplotypes over 200 kb regions. 
 
3. Results 
 
3.1. WES and rare variants 
First, we analyzed the WES data set as it represents all exonic variants, of which the study 
design has 65% power to detect a rare variant association signal considering individual 
genes. Testing the aggregated effect of grouped variants within a gene set has the potential 
to increase power. Supplementary Table 4 shows the re-sults of the gene set analyses in the 
WES data set. Common exonic variants are moderately associated to PD. The nominal p-
value is signiﬁcant, but the empirical p-value exceeds 0.05. Although we anticipated a 
signiﬁcant association of common variants, we attri-bute the moderate association to a 
relatively low sample size (compared to the original GWAS) and the selection of genes (by 
Prix ﬁxe) with variants in moderate LD with the original highest SNP. 
 
 
The gene set association is absent when focusing on the common amino acid changing and 
CADD variants, which is probably due to a decrease in power as the number of variants 
drops. 
No rare variant or common and rare variant associations were observed for the gene set in 
either of the functional variant cate-gories (nominal p ฀ 0.223; Supplementary Table 4). An 
alternative approach to study the putative rare variant associations is to test each gene 
individually within the gene set. Table 2 displays the 3 strongest associated genes per 
functional category. Using the AAchanging variants category, we observed a signiﬁcant 
association for STBD1 (p ¼ 0.046). 
3.2. NeuroX and rare variants 
The NeuroX data set contains previously identiﬁed exonic vari-ants, of which a large 
proportion is rare (Nalls et al., 2015). In contrast to the WES data sets, our NeuroX cohort 
has enough power (estimated at 96%), due to the larger sample size (6804 cases 5970 
controls), to detect a rare variant association signal. Similarly, to the WES data set, a 
moderate common variant association is detected (nominal p ¼ 0.031). In contrast to the 
WES data set, we do observe signiﬁcant associations of the gene set with PD, even when 
only considering rare variants (AAchanging ¼ 0.007; CADD ¼ 0.002; Supplementary Table 
5a). 
To discover whether speciﬁc genes drive this observed rare variant association as observed 
in our cohort, the variants were grouped per gene and 2-sided tested for their association to 
PD. 
LRRK2 is the gene driving the association observed in the total gene sets (Supplementary 
Table 6). Focusing on the CADD subset, this association (nominal p ¼ 5.17 ฀ 10฀13) is 
considerably stron-ger than the second most signiﬁcant SPATA19 (nominal p ¼ 0.050). The 
NeuroX array custom content is primarily driven by neuro-degenerative diseases; therefore, 
NeuroX chip biases toward capture of in-depth genetic variability within genes, which are 
known to cause disease pathogenesis (Tennessen et al., 2012). Likewise, NeuroX harbors 
many variants of the known PD genes. For example, NeuroX contains 32 harmful (predicted 
by CADD) LRRK2 variants, whereas only 2 harmful variants are present for SPATA19.The 
variants in LRRK2 are overrepresented and biasing the results of the total gene sets. We, 
therefore, performed the same gene set analyses on the NeuroX data set excluding the 
variants of LRRK2 (Supplementary Table 5b), resulting in the absence of a rare variant 
association in the NeuroX data set (nominal p ฀ 0.28). This suggests that the previously 
observed association of rare variants within the total gene set to PD was solely driven by 
LRRK2. 
The 2-sided SKAT analysis per gene aimed at the discovery of genes driving the rare variant 
association in the total gene set. Next, we were interested to explore the genetic burden of 
rare variants for each gene individually when assuming all rare variants to have the same 
direction of effect (1-sided BURDEN test). Table 3 shows again that LRRK2 is the strongest 
associated gene. Furthermore, SPATA19 (p ¼ 0.017) is signiﬁcantly associated when 
speciﬁcally considering rare CADD variants. 
3.3. Directionality of effect 
We further explored the signiﬁcant individual association signals (empirical p < 0.05) for 
LRRK2 and STBD1, and SPATA19.By focusing on the variant level, we aimed to comprehend 
the di-rection of effect estimates. LRRK2 showed a signiﬁcant burden of 32 rare damaging 
variants in the NeuroX data set. Single-marker association analysis of LRRK2 variants 
revealed that the observed association (p ¼ 3.17 ฀ 10฀13) is attributed to the p.G2019S 
(rs34637584), the most common cause of monogenetic forms of PD. Interestingly, this 
particular variant was present in 78 cases (MAF ¼ 0.006). Performing the rare variant 
aggregation test on 31 pathogenic LRRK2 variants, excluding p.G2019S, resulted in no 
association (p ¼ 0.98) to PD, and thus suggesting that the observed rare variant association 
in LRRK2 was solely driven by the p.G2019S variant. As this variant is only present in 7 cases 
in the WES data set (MAF ¼ 0.003) with a single-marker p-value of 0.002 (LRRK2 mutations 
generally observed in late-onset PD), it explains the discrepancy of results for LRRK2 locus as 
observed in the WES data set, whereas it showed a strong association in the NeuroX data 
set. 
In addition to the rare variant association test in LRRK2,we explored the presence of the 
previously published common LRRK2 haplotype with a protective effect of 3 exonic variants 
(p.N551K-p.R1398H-p.K1423K) (Ross et al., 2011). p.K1423K is not included in the NeuroX 
genotyping array but is in high linkage disequilibrium (r2 ¼ 1.00) with p.R1398H. We 
therefore tested the p.N551K-p.R1398H (G-A) haplotype and conﬁrmed the protective 
effect (OR ¼ 0.89, p ¼ 0.027) of this haplotype for the PD cases, showing a minor haplotype 
frequency of 6.2% in cases and 6.9% in controls. All 3 variants were detected in the WES 
data set, allowing to test the full haplotype (G-A-A). Although the haplotype association was 
not signiﬁcant in the WES data set (OR ¼ 0.81, p ¼ 0.223), the trend of effect is similar with a 
minor haplotype frequency of 7.0% in cases and 7.5% in controls. The smaller sample size of 
the WES data set is a plausible reason for not obtaining a signiﬁcant association. 
Next, the WES-based STBD1 and NeuroX-based SPATA19 were investigated for their variant 
frequencies. Single-marker associa-tion analysis showed no signiﬁcant results for the 8 
variants within STBD1. It therefore appears that the observed rare variant associa-tion is not 
caused by 1 exclusive variant but is rather the effect of multiple rare variants. Seven of the 8 
variants are control-speciﬁcas they are only present in 10 control individuals. In contrast, 
only 1 variant is present in a single case. The direction of effect of the variants that are 
generating the STBD1 gene association is therefore implied to be protective. The signiﬁcant 
gene-based association for SPATA19 is relatively strong considering that it is driven by only 2 
CADD variants that are present in 7 cases and 0 controls. The absence of SPATA19 CADD 
variants in controls suggests that the association signal is damaging. 
 
 
 
 
4. Discussion 
 
    To establish the inﬂuence of rare variants in sporadic PD risk loci, we explored 2 
independent PD data sets (WES and NeuroX) enriched for coding rare variants. We 
used the Prix ﬁxe strategy to select the most likely causal genes underlying the PD 
loci peaks, which is based on overlapping biological functional similarities. We tested 
both the effect of rare variants in the gene sets at once, as each gene individually. 
Aggregating variants simultaneously across a set of genes has the potential to 
increase power to detect an as-sociation signal, given that the selected genes are 
enriched for a group of genes that are genuinely involved in the disease 
pathogenesis. 
     The average age of onset within the cases of the WES data set (w41 years) is 20 
years younger than in the meta-analysis of the most recent PD GWAS (w61 years) 
where the PD risk loci were based on. As some rare genetic risk factors (DJ-1, parkin 
PINK1)(Bras et al., 2015) are speciﬁc for young onset PD (YOPD), we acknowl-edge 
the putative existence of YOPD-speciﬁc common genetic risk factors within the WES 
data set. However, risk factors related to late-onset sporadic PD might also play a 
role in YOPD. PD risk loci, such as SNCA and GBA (Klein and Westenberger, 2012; 
Nalls et al., 2014) overlap between late and young onset. We therefore expect that 
our WES data set is an adequate data set to study the rare exonic variants in PD risk 
loci. Furthermore, YOPD is often geneti-cally explained through rare variants (Bras et 
al., 2015). The YOPD patient group in the WES data set could therefore be enriched 
for cases which are genetically inﬂuenced by rare variants, possibly increasing the 
likelihood of detecting rare variant association. 
     Using gene set approach in the WES data set, we did not detect a burden of rare 
variants when comparing PD subjects to controls. However, it is undetermined 
whether the absence of a rare variant association is genuine or due to insufﬁcient 
power. A genuine rare variant association might furthermore be impeded by the 
gene set composition. By using Prix ﬁxe, we increase the likelihood of selecting the 
truly involved PD genes underneath the known PD risk loci, yet unrelated genes 
might still be included, possibly diluting an association signal. In contrast, with the 
gene-based as-sociation test for the genes selected with the Prix ﬁxe strategy, we 
observed a rare variant association for STBD1, implying that rare variants in this gene 
could decrease the risk to develop PD. STBD1 has its function in lysosomal-mediated 
autophagy to speciﬁcally guide glycogen to lysosomes for sequestration and 
degeneration (Jiang et al., 2011). It, therefore, seems that variants in STBD1 could 
have beneﬁcial effects for the removal of glycogen. The lysosomal-mediated 
autophagy has been implied to be involved in PD through the association of multiple 
genes, such as LRRK2, ATP13A2, and GBA (Trinh and Farrer, 2013). However, the 
involvement of STBD1 in PD pathogenesis has to be carefully considered, as we 
currently did not have an adequate independent data set to replicate the 
associationthat was generally based on singletons. The NeuroX genotyping array 
typically includes variants that have been observed in previ-ous data sets, minimizing 
the probability to detect similar single-tons with an extremely low minor allele 
frequency. Only 3 of the 8 STBD1 variants of the WES data set were present within 
the NeuroX data set reducing the power to detect the single gene association. 
Hence, further genetic validation studies are warranted to establish the role of 
STBD1 in PD. Once a legitimate replication is realized, functional assays on 
lysosomal-mediated autophagy should further decipher the contribution of STBD1, 
preferably in relation to well-established PD genes. 
    We detected a strong association of rare variants within the gene sets for the 
NeuroX data set. However, subsequent analyses showed that these associations 
were dominated by LRRK2 variants. Asso-ciation analysis on variant level revealed 
that the LRRK2 gene signal was driven by the known p.G2019S variant. This 
observation highlights the importance of cataloguing the individual rare vari-ants to 
fully resolve the impact of rare variants in disease suscep-tibility for PD. As shown for 
the LRRK2 association and even the total gene set association, it is driven by only 1 
variant, which also could have been detected with the performance of a simple 
single-marker association test. Besides the pathogenic association signal of rare 
variant p.G2019S, we observed a signiﬁcant protective effect of a previously 
published common haplotype (Ross et al., 2011). This observation supports the 
theory that other variants with opposite effects could interact and potentially 
inﬂuence the penetrance of pathogenic LRRK2 variants, such as p.G2019S. Besides 
LRRK2,we furthermore detected a NeuroX-based burden of rare CADD vari-ants for 
SPATA19 that increases PD risk (p ¼ 0.017). This association signal is relatively strong 
considering that it is driven by only 2 CADD variants that are present in 7 cases and 0 
controls. As SPATA19 is involved in spermatogenesis (Nourashrafeddin et al., 2014) 
and the GTEx portal displays speciﬁc high expression for the testis, it diminishes the 
likelihood that defects of this gene would contribute to neurodegeneration. Further 
genetic and functional studies are warranted to decipher a role of this gene in PD. 
 
In contrast to selecting the physically closest gene to the strongest SNP within each 
PD locus, we followed a comprehensive strategy to deﬁne true causal gene, which is 
based on biological similarities. As we expect that only 1 gene per locus is the true 
causal gene, we did not deﬁne a gene set including all the genes underneath the 
GWAS loci assuming that the overrepresentation of noncausal genes would dilute a 
putative association signal. We acknowledge that the ultimate strategy to test the 
effect of rare variants in the PD loci would be to sequence all genes in a large cohort 
and test the effect of rare variants in each gene individually. Furthermore, 
sequencing rather than genotyping will deﬁne novel rare variants and contribute to 
cataloguing the inﬂuence of rare variants underneath the PD risk loci. Acknowledging 
these caveats, our study suggests for the ﬁrst time that, apart from LRRK2, SNCA, 
and GBA, other common PD risk loci might harbor rare variants that contribute to PD 
risk. 
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